Sugi Predict

Sugi Predict / Compounds / SCHEMBL343604

SCHEMBL343604

SCHEMBL343604

O=[N+]([O-])c1ccc(Cl)c(O)c1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.67
▸ GPR35 Q9HC97 3/20 0.62
▸ ALDH1A1 P00352 5/20 0.57
▸ HPGD P15428 2/20 0.57
▸ TSHR P16473 2/20 0.57
▸ SMN1; SMN2 Q16637 2/20 0.57
▸ TP53 P04637 1/20 0.57
▸ MAPK1 P28482 1/20 0.57
▸ GAA P10253 3/20 0.55
▸ THRB P10828 1/20 0.55
▸ VCAM1 P19320 1/20 0.55
▸ KMT2A Q03164 4/20 0.53
▸ ERN1 O75460 1/20 0.52
▸ RORC P51449 1/20 0.51
▸ MEN1 O00255 2/20 0.49
▸ POLB P06746 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.48
▸ ALOX15 P16050 1/20 0.48
▸ MAPT P10636 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL140502 0.83 HSD17B10 (0.67) HSD17B10GPR35ALDH1A1HPGDTSHR
SCHEMBL14353306 0.82 HSD17B10 (0.64) HSD17B10GPR35ALDH1A1HPGDTSHR
SCHEMBL28875736 0.82 HSD17B10 (0.64) HSD17B10GPR35ALDH1A1HPGDTSHR
SCHEMBL27467381 0.82 HSD17B10 (0.64) HSD17B10GPR35ALDH1A1HPGDTSHR
Potassium Ion SCHEMBL14353304 0.82 HSD17B10 (0.64) HSD17B10GPR35ALDH1A1HPGDTSHR
SCHEMBL17502049 0.81 MEN1 (0.66) HSD17B10GPR35ALDH1A1SMN1; SMN2MAPK1
SCHEMBL17502051 0.81 MEN1 (0.66) HSD17B10GPR35ALDH1A1SMN1; SMN2MAPK1
4-Nitrocatechol SCHEMBL11765698 0.80 TSHR (0.69) HSD17B10GPR35ALDH1A1HPGDTSHR
4-Nitrocatechol SCHEMBL156909 0.80 TSHR (0.69) HSD17B10GPR35ALDH1A1HPGDTSHR
SCHEMBL85918 0.80 HSD17B10 (1.00) HSD17B10GPR35ALDH1A1TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 645 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117486735-A Method for synthesizing 2-chloro-5-aminophenol by fixed bed reactor 山东兴文工业技术研究院有限公司 2024-02-02 — — CN claimed
CN-111499622-B Preparation method of medicine for treating bile duct cancer 山东省科学院菏泽分院 2023-06-06 — — CN claimed
CN-112495418-A Preparation method of nitrogen-doped carbon-supported non-noble metal catalyst and application of nitrogen-doped carbon-supported non-noble metal catalyst in reduction of nitro compounds 山东科技大学 2021-03-16 — — CN claimed
CN-111499622-A Preparation method of medicine for treating bile duct cancer 山东省科学院菏泽分院 2020-08-07 — — CN claimed
CN-109956895-A A kind of procymidone haptens and its synthetic method and application 深圳市易瑞生物技术股份有限公司 2019-07-02 — — CN claimed
CN-106336385-B The synthetic method of Yi Zhong Evil humulones 江苏丰华化学工业有限公司 2018-05-11 — — CN claimed
CN-105621587-B A kind of method using potentiometric titrations degradating chloro nitro-aromatic 浙江大学 2018-01-23 — — CN claimed
CN-105646231-B A kind of preparation method of the nitrophenol of 2,4 dichloro 5 连云港市金囤农化有限公司 2017-09-22 — — CN claimed
CN-106336385-A Oxadiazon synthesis method 江苏丰华化学工业有限公司 2017-01-18 — — CN claimed
CN-105837402-A Preparation method for 2,4-dichloro-5-bromotoluene 常州大学 2016-08-10 — — CN claimed
CN-1271027-C Method of synthesizing dihalogenated aromatic ether by phase transfer JIAXING COLLEGE (CN) 2006-08-23 — — CN claimed
US-20050182088-A1 Modulators of acetylcholine receptors MERCK SHARP & DOHME CORP. 2005-08-18 — — US claimed
CN-1651380-A Method of synthesizing dihalogenated aromatic ether by phase transfer JIAXING COLLEGE (CN) 2005-08-10 — — CN claimed
US-20050070520-A1 Aza-cyclic compounds as modulators of acetylcholine receptors MERCK SHARP & DOHME CORP. 2005-03-31 — — US claimed
EP-1472248-A1 MODULATORS OF ACETYLCHOLINE RECEPTORS ELI LILLY AND COMPANY (US) 2004-11-03 — — EP claimed
EP-1467986-A1 AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS ELI LILLY AND COMPANY (US) 2004-10-20 — — EP claimed
WO-2003062224-A1 AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS ELI LILLY AND COMPANY (US) 2003-07-31 — — WO claimed
WO-2003062235-A1 MODULATORS OF ACETYLCHOLINE RECEPTORS ELI LILLY AND COMPANY (US) 2003-07-31 — — WO claimed
EP-0299891-B1 PROCESS FOR THE SELECTIVE CHLORINATION OF PHENOLIC COMPOUNDS RHONE-POULENC CHIMIE (FR) 1991-12-11 — — EP claimed
EP-0299891-A1 Process for the selective chlorination of phenolic compounds RHONE-POULENC CHIMIE (FR) 1989-01-18 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070520-A1 Aza-cyclic compounds as modulators of acetylcholine receptors CHRNG, CHRNA4, CHRNB4 HSD17B10 2835/4885GPR35 202/4885ALDH1A1 1088/4885
US-20050182088-A1 Modulators of acetylcholine receptors CHRM3, CHRNG, CHRM5 HSD17B10 1779/4885GPR35 246/4885ALDH1A1 1036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.